Orphan drugs, those medications that are typically produced in small quantities for limited patient populations, are growing in importance worldwide. Once largely considered too costly to produce, given the limited number of patients affected by a particular disease, new technology and new breakthroughs in biopharma have changed the landscape, allowing more orphan drugs to be produced, thus saving countless lives that would otherwise be lost. But bringing an orphan drug to market has its own unique set of challenges. World Courier addresses the considerations that must be overcome.
Getting a clinical trial drug into China is a complex business. Any discrepancies in paperwork or the physical shipment can lead to delays at customs or China Inspection & Quarantine. World Courier shares its experience for successful shipping.
Down at the base of Africa is a country with amazing heritage, unique geography, and challenging patient populations. See why clinical trials happen in South Africa here
In globalising the pharmaceutical industry oversight and control has increasingly become a challenge in managing product quality, consumer safety and organisational risk.
Once deficiencies in the supply chain are identified, how can the pharmaceutical industry ensure it manages product quality, consumer safety and organizational risk?
Southeast Asia is a growing pharmaceutical market, with a population of 620 million. What opportunities are there for multinational companies to access this rich area?